Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine–hyaluronic acid conjugate
- 31 July 2010
- journal article
- Published by Elsevier BV in Biomaterials
- Vol. 31 (19), 5258-5265
- https://doi.org/10.1016/j.biomaterials.2010.03.018
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education, Science and Technology (2009-0072986, 2009-0081871)
This publication has 37 references indexed in Scilit:
- VEGF siRNA Delivery System Using Arginine-Grafted Bioreducible Poly(disulfide amine)Molecular Pharmaceutics, 2008
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Breaking up the correlation between efficacy and toxicity for nonviral gene deliveryProceedings of the National Academy of Sciences of the United States of America, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Tumor-Targeting Nanoimmunoliposome Complex for Short Interfering RNA DeliveryHuman Gene Therapy, 2006
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivoGene Therapy, 2004
- Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complexBiomaterials, 2004
- The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan.The Journal of cell biology, 1992